Recent Updates
Recently added Catalysts

vobramitamab duocarmazine

Phase 1

Advanced Solid Tumor | Monoclonal antibody | Oncology |MacroGenics, Inc.|Last Updated: Oct 14, 2025

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
CONTROLLEDBiomarker
Total Trials1
Total Enrollment31
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT05293496A Study of MGC018 in Combination With MGD019 in Participants With Advanced Solid TumorsPHASE1 COMPLETED 31 — — Apr 19, 2022Aug 26, 2025Oct 14, 202510 United States
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Number of participants with adverse events (AEs)
Up to 2 years
Number of participants with serious adverse events (SAEs)
Up to 2 years
Number of participants with AEs leading to study treatment discontinuation
Up to 2 years
Secondary Endpoints
Mean maximum observed concentration (Cmax) of vobramitamab duocarmazine
Throughout the study, up to 2 years
Mean maximum observed concentration (Cmax) of lorigerlimab
Throughout the study, up to 2 years
Mean time to maximum concentration (Tmax) of vobramitamab duocarmazine
Throughout the study, up to 2 years
Unlock Study Endpoints
Study Design & Arms
AllocationNON_RANDOMIZED
MaskingNONE
ModelSEQUENTIAL
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
Cohort -1EXPERIMENTALvobramitamab duocarmazine at dose level -1 and lorigerlimab intravenously (IV) every 4 weeks
Cohort 1EXPERIMENTALvobramitamab duocarmazine at dose level 1 and lorigerlimab IV every 4 weeks
Cohort 2EXPERIMENTALvobramitamab duocarmazine at dose level 1 and lorigerlimab IV every 4 weeks
Cohort 3EXPERIMENTALvobramitamab duocarmazine at dose level 2 and lorigerlimab IV every 4 weeks
Cohort 4EXPERIMENTALvobramitamab duocarmazine at dose level 3 and lorigerlimab IV every 4 weeks
Cohort 5EXPERIMENTALvobramitamab duocarmazine at dose level 4 and lorigerlimab IV every 4 weeks
Cohort ExpansionEXPERIMENTALmaximum tolerated dose of vobramitamab duocarmazine and lorigerlimab IV every 4 weeks
Interventions
NameTypeDescription
vobramitamab duocarmazineBIOLOGICALVobramitamab duocarmazine is an antibody drug conjugate (ADC) targeted against B7-H3.
lorigerlimabBIOLOGICALLorigerlimab is a bispecific DART® molecule that binds PD-1 and CTLA-4.
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — N/A
SexALL
Healthy VolunteersNo
Study Sites10

Inclusion Criteria: * 1\. Ability to provide and document informed consent and willing and able to comply with all study procedures. * Participants diagnosed with advanced solid tumors including but not limited to metastatic castration-resistant prostate cancer, melanoma, pancreatic cancer, hepatoc...

Countries:United States
Unlock Eligibility Criteria
Competitive Landscape -Other Solid Tumors 9 trials
CompanyTickerTrialsLead PhaseDrugs
Merck & Co., Inc.MRK2PHASE2pembrolizumab, V503, GARDASIL
Incyte CorporationINCY1PHASE2Chemotherapy, Retifanlimab
Novartis AG Sponsored ADRNVS1PHASE1KFA115, pembrolizumab
Iovance Biotherapeutics IncIOVA2PHASE2E7 TCR-T cells, Aldesleukin
AstraZeneca PLCAZN1 — Trastuzumab deruxtecan
Unlock Competitive Intelligence